Cargando…
ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus
Accumulated knowledge in the molecular processes of tumour development combined with the availability of genetically modified viruses resemble the basis for new promising cancer therapeutics. The main advantages of employing replication-competent viruses are achievement of tumour selective killing a...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2002
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746528/ https://www.ncbi.nlm.nih.gov/pubmed/11857003 http://dx.doi.org/10.1038/sj.bjc.6600006 |
| Sumario: | Accumulated knowledge in the molecular processes of tumour development combined with the availability of genetically modified viruses resemble the basis for new promising cancer therapeutics. The main advantages of employing replication-competent viruses are achievement of tumour selective killing and amplification of their oncolytic potential within the tumour mass. In this review, we describe the development of ONYX-015, one of the first and most advanced replication-competent viruses for cancer therapy. We discuss the molecular biology of this therapeutic approach and the interesting results obtained with this virus in clinical trials. British Journal of Cancer (2002) 86, 5–11. DOI: 10.1038/sj/bjc/6600006 www.bjcancer.com © 2002 The Cancer Research Campaign |
|---|